ALK and non-small cell lung carcinoma: In this retrospective analysis, we evaluated the treatment course and clinical efficacy of ALK‐TKI in ALK‐positive NSCLC patients who received rebiopsy after relapse on ALK‐TKI, and the administration of ALK‐TKIs based on the secondary sensitive mutations was associated with a high ORR and relatively short PFS (87.5% and 5.4 months, respectively).